Prelude Capital Management’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Prelude Capital Management’s Portfolio KRSA Stock Details KRSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-661	Closed	-$80K	–	1381
2022 Q3	$80K	Sell	661 -240	-27%	-$4.13K	﹤0.01%	1194
2022 Q2	$69K	Buy	901 +185	+26%	+$2.65K	﹤0.01%	1461
2022 Q1	$111K	Buy	716 +162	+29%	+$3.9K	﹤0.01%	1390
2021 Q4	$133K	Buy	554 +250	+82%	+$11.8K	﹤0.01%	1660
2021 Q3	$131K	Sell	304 -54	-15%	-$3.53K	﹤0.01%	1458
2021 Q2	$195K	Buy	+358	New	+$22.4K	0.01%	1386
2019 Q4	–	Sell	-7	Closed	-$12K	–	1971
2019 Q3	$12K	Buy	+7	New	+$1.51K	﹤0.01%	1469

Other funds holding KRSA

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TFS

TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Prelude Capital Management's KRSA Position: Q4 2022 in Review

Prelude Capital Management sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q4 2022, closing a stake of 661 shares — an estimated $80K sold.

Prelude Capital Management first reported a position in KRSA in Q3 2019 and held it in 7 quarters. The position peaked at $195K in Q2 2021. 33 funds tracked by Wall St. Rank hold KRSA as of Q4 2022.

Prelude Capital Management reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Prelude Capital Management sold 661 Korsana Biosciences, Inc. Common Stock shares in Q4 2022, an estimated $80K.
Prelude Capital Management first reported a position in Korsana Biosciences, Inc. Common Stock in Q3 2019 and held it in 7 quarters.
Prelude Capital Management's Korsana Biosciences, Inc. Common Stock position peaked at $195K in Q2 2021.
33 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q4 2022.

Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.